Brain-penetrant enzyme replacement therapy improves biomarkers in mucopolysaccharidosis type II
1. In this open-label phase 1–2 study, pediatric patients with mucopolysaccharidosis type II treated with tividenofusp alfa showed substantial reductions ...
